JS111 capsules (AP-L1898)
Preclinical
JS111 capsules (AP-L1898) is one of 9 therapeutic programs targeting NSCLC. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
14 competitors in NSCLC
#DrugCompanyPhaseTrials
1Taxotere
AAvyxa
Phase 3
Alunbrig
TakedaPhase 2
Poziotinib
Spectrum Pharmaceuticals, IncPhase 3
Tyrosine Kinase Inhibitor
PfizerPhase 2
SKB264
SSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
SYS6010
CCSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1
Alimta
GGynecologic Oncology Group
Preclinical
Platinum Chemotherapy
RochePreclinical
JS111 capsules (AP-L1898)
SSuzhou Junjing BioSciences Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for JS111 capsules (AP-L1898). EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]